$6.86
0.44% yesterday
Nasdaq, Nov 25, 10:00 pm CET
ISIN
CA98400H1029
Symbol
XBIT
Sector
Industry

XBiotech, Inc. Stock price

$6.86
-0.31 4.32% 1M
-1.45 17.45% 6M
+2.86 71.50% YTD
+3.11 82.93% 1Y
-6.01 46.70% 3Y
-4.27 38.35% 5Y
-13.69 66.62% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.03 0.44%
ISIN
CA98400H1029
Symbol
XBIT
Sector
Industry

Key metrics

Market capitalization $209.12m
Enterprise Value $36.00m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.09
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-42.31m
Free Cash Flow (TTM) Free Cash Flow $-29.19m
Cash position $183.12m
EPS (TTM) EPS $-1.07
Short interest 4.76%
Show more

Is XBiotech, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

XBiotech, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast XBiotech, Inc.:

1x Hold
100%

Analyst Opinions

1 Analyst has issued a forecast XBiotech, Inc.:

Hold
100%

Financial data from XBiotech, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
- -
-
100%
- Direct Costs 1.74 1.74
2% 2%
-
-1.74 -1.74
18% 18%
-
- Selling and Administrative Expenses 1.09 1.09
27% 27%
-
- Research and Development Expense 38 38
17% 17%
-
-41 -41
15% 15%
-
- Depreciation and Amortization 1.74 1.74
1% 1%
-
EBIT (Operating Income) EBIT -42 -42
14% 14%
-
Net Profit -33 -33
41% 41%
-

In millions USD.

Don't miss a Thing! We will send you all news about XBiotech, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

XBiotech, Inc. Stock News

Neutral
GlobeNewsWire
5 months ago
Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha Therapy

Company Profile

XBiotech, Inc. is a biopharmaceutical company. The firm engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.

Head office Canada
CEO John Simard
Employees 82
Founded 2005
Website www.xbiotech.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today